Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles by Natasha Yetman

Five Charged in U.S. with Stealing Secrets from GlaxoSmithKline

Bill Berkrot  |  

REUTERS—Five people, including two former GlaxoSmithKline researchers, were charged with a scheme to steal trade secrets from the British drugmaker for potential sale in China, according to indictments announced by the U.S. Attorney’s Office in Philadelphia on Wednesday. The indictments include charges of conspiracy to steal trade secrets, conspiracy to commit wire fraud, conspiracy to…

U.S. Government Suspends Enrollment in Cigna Medicare Advantage, Drug Plans

Caroline Humer  |  

(Reuters)—The U.S. government has suspended new enrollment in Cigna Corp’s Medicare Advantage health plans for seniors and standalone Medicare prescription drug plans, citing noncompliance in its appeals and grievances procedures. The government said Cigna had deficiencies in its appeals and grievances processes in both Medicare Advantage and the Medicare prescription drug program, according to a…

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Laura Newman  |  

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…

U.S. Top Court Rejects New Challenge to Obamacare

Lawrence Hurley  |  

WASHINGTON (Reuters)—The U.S. Supreme Court, which delivered major rulings in 2012 and 2015 preserving President Barack Obama’s signature healthcare law, on Tuesday declined to take up a new, long-shot challenge to Obamacare brought by an Iowa artist. The court turned away an appeal by Matt Sissel, who had asserted that the 2010 Affordable Care Act…

Patients Are Essential to Grassroots Advocacy

Kelly Weselman, MD  |  

In 2015, ACR members were powerful advocates on important issues affecting public health and rheumatology. But we should not forget about an important resource—patients, each of whom can bring unique perspectives to legislators in Washington, D.C. Working together, our voices are stronger. Here’s how your patients can work with the ACR to advocate for their health and rheumatology…

High-Deductible Health Plan Enrollees Aren’t Shopping Around

Kathryn Doyle  |  

hgh(Reuters Health)—High-deductible health insurance plans have been tied to lower healthcare spending, but a new study suggests the reason is not that enrollees in those plans are savvier. High-deductible plans have lower premiums, but when enrollees need medical care, it costs them more out-of-pocket. Researchers had expected that these patients are spending less because they’re…

French ‘Cannabis’ Drug Trial Volunteer Dies

Reuters Staff  |  

RENNES, France (Reuters)—A man left brain dead after a drug trial in northwest France died on Sunday, said the hospital where he was being treated. The Rennes hospital said in a statement that five other volunteers were in stable condition after they were admitted last week. In total, 90 people took part in the trial of the drug made…

French ‘Cannabis’ Drug Trial Leaves 1 Brain Dead, 5 Injured

Matthias Blamont  |  

PARIS (Reuters)—One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in western France of an experimental medicine from an unnamed drug company, the French health ministry said on Friday, Jan. 15. The ministry did not say what the medicine was intended to be used…

Drug Shortages in U.S. Emergency Departments on the Rise

Madeline Kennedy  |  

(Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…

U.S. Patent Office Rules Against Amgen Humira Challenge

Bill Berkrot  |  

(Reuters)—U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie’s Humira (adalimumab), a potential setback in Amgen efforts to market a biosimilar version of the world’s top-selling prescription medicine. In June, Amgen, the world’s biggest biotechnology company, asked the U.S. Patent and Trademark Office for the review, arguing that…